Energy
PrivateA real, low-cost ISR producer riding the best uranium tape in 18 years — but the FY25 income statement is a financing-and-divestiture story (Verdera gain + $115M converts), not an extraction story; until contracted ceilings reset and Alta Mesa proves >1.5Mlb/yr at $30s cash cost, this is a high-torque option on U3O8 with a governance/controls cloud, not a compounding miner.
Research
The verdict
A real, low-cost ISR producer riding the best uranium tape in 18 years — but the FY25 income statement is a financing-and-divestiture story (Verdera gain + $115M converts), not an extraction story; until contracted ceilings reset and Alta Mesa proves >1.5Mlb/yr at $30s cash cost, this is a high-torque option on U3O8 with a governance/controls cloud, not a compounding miner.
Primary sources
Source documents — open to read in full
enCore Energy is a US-focused in-situ recovery (ISR) uranium producer incorporated in British Columbia, HQ'd in Dallas, dual-listed on Nasdaq + TSX-V under "EU". It is one of only a handful of companies worldwide operating more than one uranium extraction facility, and owns three of the ten licensed-and-constructed ISR central processing plants (CPPs) in the US, all in Texas.
How it makes money: ISR dissolves uranium in place (oxygenated groundwater pumped through a wellfield), pumps the pregnant solution to a CPP where U3O8 is captured on ion-exchange resin, then eluted, dried and packaged as "yellowcake." enCore sells that U3O8 to US nuclear utilities under spot-referenced contracts with annual-escalating floor and ceiling prices, plus one legacy contract with a uranium trader. The model's appeal vs. conventional mining: low capital intensity, fast wellfield cycle times, smaller environmental footprint, and the ability to flex output by adding satellite wellfields feeding a central plant.
Key assets:
Customers / contract structure: Highly concentrated. In FY25 three external customers accounted for 100% of revenue ($27.231M / $10.980M / $4.944M — i.e. ~63% / 25% / 11%). Total committed book ~4.25M lbs U3O8 over 2023–2032 across ~7 utility contracts + 1 legacy trader contract. Contracts are spot-related with floor (margin-protective) and ceiling prices escalated annually for inflation — the ceiling is why FY25 realized price ($65.89/lb) lagged spot ($80s).
Critical nuance most coverage misses: enCore sells more uranium than it extracts, plugging the gap with purchased spot uranium. FY25: sold 655k lbs = 245k purchased + 410k extracted; FY24: 720k lbs = 580k purchased + 140k extracted. It is part miner, part uranium trader — and the trading leg is margin-thin to negative when spot rises faster than its contract ceilings.
ISR uranium has a short physical chain; the leverage points are wellfield deliverability, consumables, drilling contractors, and the conversion/enrichment bottleneck downstream. Named stakeholders:
Upstream (into enCore):
enCore (the converter of in-ground resource → drummed U3O8): Rosita CPP (800k lb/yr), Alta Mesa CPP (1.5M lb/yr), plus relocatable satellite IX plants feeding the central plants — the "hub-and-spoke" ISR model.
Downstream (out of enCore):
Chokepoints / single-source dependencies: (1) Alta Mesa is the company — Rosita is essentially offline, so a single CPP carries ~99% of extraction. (2) Drilling-contractor availability gates wellfield growth. (3) The spot market is a hidden input — a spot spike hurts the purchased-pounds leg. (4) Permitting (NRC/EPA + state) gates every new wellfield/project.
What's genuinely defensible:
Where the "moat" is weak:
Net: the moat is "licensed operating US ISR capacity in a policy-favoured, supply-short market." That is a genuine and scarce thing. It is not a low-cost-vs-the-world or brand moat, and it is fragile to a uranium-price reversal.
enCore reports a single segment — extraction, recovery and sale of US uranium — with all assets in the US. There is no product or geographic segmentation to disaggregate; the meaningful "segments" are operational:
By revenue source (FY25, $43.155M total):
By volume mix (the real story — extracted vs purchased lbs):
| Year | Total lbs sold | Extracted lbs | Purchased lbs | Extracted cash cost/lb | Realized price/lb |
|---|---|---|---|---|---|
| FY25 | 655,000 | 410,000 | 245,000 | $28.79 | $65.89 |
| FY24 | 720,000 | 140,000 | 580,000 | $31.40 | $81.02 |
Trend & cause: Total extraction grew ~700k lbs FY25 vs ~300k lbs FY24 (>100%) as Alta Mesa ramped (it began extraction Q2 2024). But realized price fell 19% ($81.02→$65.89) because contract ceilings capped the upside while spot ran. Revenue therefore fell 26% even as production doubled — the central paradox of FY25. The mix is shifting the right way (more own-extraction, less low-margin purchased pounds), but the contracted ceilings mute the benefit of the price super-cycle. Q1 2026 extraction 90,000 lbs (+22% YoY) confirms the ramp continues.
Latest print — Q1 2026 (qtr ended 2026-03-31, filed 2026-05-14):
The headline "enCore swings to profit" is misleading. The Q1 profit is a one-time disposal gain on a related-party spin-off, partly offset by mark-to-market losses on the company's equity portfolio. The underlying uranium business ran a gross loss and a ~$24M operating loss. Strip non-operating items and Q1 2026 looks like every other quarter: a sub-scale producer selling ceiling-capped pounds and buying spot to fill the book.
FY2025 full year:
Guidance / outlook: No formal numeric production guidance in the 10-K; strategy is "phased growth" around Rosita + Alta Mesa, satellite-IX expansion, and advancing Dewey Burdock. Sell-side models (Cantor: "Speculative Buy," PT $5.00 cut from $5.50) imply a sharp production + margin ramp not yet evident in the filings.
Balance-sheet flags (FY25):
Market reaction: EU collapsed from a ~$523M non-affiliate market value (Jun 2025, ~$2.71/sh implied) to ~$1.35–1.62 (June 2026). A ~36% single-day drop hit in March 2025 coincident with the class-action filing and control disclosures. The market has de-rated this name hard even as uranium prices sit at 18-year highs — a stark divergence (see Lens 8/12).
No earnings-call transcripts are on the research-layer shelf (transcripts/ empty; transcripts=0). Reconstructed from filings + IR/press + sell-side coverage; figures labeled accordingly.
Management focus, FY24 → Q1 2026 (trajectory):
Phrases recurring: "supplier of choice," "domestic uranium," "phased growth," "non-dilutive," "corporate renewal," "cost management." Things they stopped saying: aggressive near-term production-target language; the prior CEO's framing. The narrative has de-risked downward from "growth producer" toward "fix the controls, manage costs, monetize non-core, ride policy." That is a more honest but less exciting story — and an admission the earlier story over-promised.
US/global uranium peers.
| Company | Ticker | ~Mkt cap (USD) | EV/Sales | P/E | Div yield | Notes |
|---|---|---|---|---|---|---|
| enCore Energy | EU | ~$0.26–0.32B | ~6–7x | n/a (loss-making) | 0% | Producing US ISR; GAAP loss |
| Cameco | CCJ | ~$52.65B | n/a | n/a | low | Global bellwether; owns Westinghouse stake |
| Uranium Energy Corp | UEC | ~$5.36B (Jun 29 '26) | 261.8x | n/a (minimal rev) | 0% | US ISR hub-and-spoke; total cost/lb ~$39.30 |
| Energy Fuels | UUUU | n/a | n/a | n/a | 0% | White Mesa mill (only US conventional) + REE/vanadium |
| Ur-Energy | URG | ~$0.243B | n/a | n/a | 0% | Wyoming ISR (Lost Creek) |
| 5-yr avg ROE (all) | — | — | — | — | — | n/a (sector loss-making through ramp) |
Read: On EV/Sales, enCore screens cheap vs the sector — ~6–7x against UEC's 261.8x. But this is apples-to-oranges: UEC's nosebleed multiple reflects a near-zero revenue base + huge embedded-physical-uranium + growth-option premium, whereas enCore has revenue but it's low-margin/loss-making with a debt + governance overhang. The honest comp statement: enCore is the cheapest US ISR producer on revenue, and the market is pricing in the execution, dilution, and controls risk rather than mispricing the asset. A re-rate requires the discount to close, which requires clean execution — not just a higher uranium price (peers already capture that). P/E is n/a / not meaningful sector-wide (the group is pre-profit through the ramp).
Mostly `` + filing-corroborated:
What the pattern reveals: EU moves on (1) uranium-sector beta (SPUT/spot), (2) deal/permitting milestones, and (3) idiosyncratic credibility shocks (the class action, the controls, the CEO churn). Unlike a clean producer, a large share of EU's variance is governance/execution-specific, not commodity-specific — which is exactly why it has underperformed the uranium price. The market reacts most violently to disclosure-integrity events.
Major turnover — this is a company on its third CEO configuration in ~2 years.
(1) Track record: Mixed. The team did build a genuine multi-plant ISR producer and 4.25M-lb contract book from a shell — real value creation. But it also over-promised on production, drew a securities class action, and had to be replaced. Little's pedigree is in monetization (the Diamondback sale), which fits enCore's current "rationalize assets, manage costs" posture more than a pure production-growth mandate.
(2) Tenure & skin in the game: New CEO (weeks). Founder Chair re-installed. Insider-ownership detail not on the research shelf [insider-transactions.csv absent]; one director (Susan Hoxie-Key) adopted a 10b5-1 plan Dec 2025. n/a — precise insider % not sourced.
(3) Capital allocation: A very active capital allocator, with mixed marks:
(4) Red flags: Related-party Verdera deal; multiple executive arbitrations; material weaknesses in ICFR (see Lens 10); a securities class action that explicitly alleges the controls/accounting were misrepresented; PFIC status (US-investor tax drag).
(5) Founder vs professional manager: Founder-led origin (Sheriff), a failed professional-management interlude, now a founder-Chair + dealmaker-CEO combo. For this stage (fix controls, monetize non-core, ride policy, possibly get acquired), the new configuration is arguably better-fit than the old — but it is unproven and carries key-person risk.
Acting as a forensic equity analyst. This is the most important section for EU — the accounting/controls issues are not hypothetical, they are disclosed and litigated.
Material weakness in internal control over financial reporting (ICFR) — disclosed. Management concluded that disclosure controls and ICFR were NOT effective as of Dec 31, 2025; material weaknesses identified as of Dec 31, 2024 were under a remediation program through FY25, "expected to support final validation". This is a live, unremediated material weakness at a producing public company — a first-order red flag. (KPMG audited the financials and issued an unqualified opinion on the statements themselves; but as a smaller-reporting/non-accelerated filer enCore is not subject to auditor attestation on ICFR under SOX 404(b) — so there is no independent ICFR sign-off).
Revenue recognition / customer concentration: 3 customers = 100% of revenue (one = 63%). Loss of any one is material. Revenue is contract-based with floor/ceiling pricing — recognition appears straightforward (delivery of drummed U3O8), but the concentration is extreme.
Cost capitalization — the core of the litigation: The class action alleges enCore "could not capitalize certain exploratory and development costs under US GAAP," which would have increased reported losses. Tellingly, in Q1 2026 enCore expensed $10.66M of "mineral property expenditures" straight through the P&L — consistent with a more conservative (expense-not-capitalize) posture post-controversy. The accounting treatment shift itself corroborates the allegation's substance.
Cash flow vs earnings divergence: enCore has negative operating cash flow and explicitly warns it "could continue for the foreseeable future" and will require "substantial additional capital". The FY25 net loss is partly non-cash (depletion, SBC, mark-to-market) but the operating cash burn is real — the company is funded by debt + equity + asset sales, not operations.
Marketable-securities mark-to-market: A $70M+ portfolio of junior-miner equities runs through earnings (FY25: +$9.6M realized / −$5.7M unrealized; Q1'26: +$3.8M / −$10.0M). This flatters or depresses GAAP results in ways unrelated to the uranium business and should be stripped for any clean read.
Non-GAAP / one-time gains: The Q1'26 "profit" is the $34.4M Verdera disposal gain — a non-recurring, related-party-sourced item. Watch for the underlying operating loss being obscured by disposal/portfolio gains.
Inventory & deferred tax: Inventory carried at lower-of-cost-or-NRV with small impairments ($76k Q1'26) — fine. A $46.9M valuation allowance sits against deferred tax assets (i.e. the company doesn't expect to use most of its $169.6M of NOLs soon — an implicit admission profitability is distant). Section 382 limits could impair NOL value if ownership changes via acquisitions.
Asset Retirement Obligations: $18.994M ARO (Q1'26); $26.1M undiscounted; $9.764M restricted cash collateralizing reclamation bonds — appropriately recognized.
Going concern: KPMG's opinion is unqualified with NO going-concern emphasis. Despite the cash burn, the $96M working capital + $52M cash + $70M securities + $18M warrant proceeds give near-term runway. So not a going-concern situation — but a needs-continuous-capital situation.
Regulatory findings (required sub-section):
EPS for FY2026–FY2028, built bottom-up from FY25 actuals + Q1'26 + the contract book. Every output ``; the uranium business is loss-making, so EPS is dominated by production scale, realized price (ceiling-capped), and non-operating items. No forecast.ts logged (watchlist mode).
Operating drivers:
Scenarios (EPS, FY ending Dec):
| FY2026E | FY2027E | FY2028E | |
|---|---|---|---|
| Bull | ~$0.05 | ~$0.15 | ~$0.30 |
| Base | ~$(0.10) | ~$(0.02) | ~$0.08 |
| Bear | ~$(0.30) | ~$(0.25) | ~$(0.15) |
Honest read: Under the base case enCore does not reach a clean, recurring operating profit until ~FY2028, when extraction approaches capacity and the contract ceilings reset toward prevailing $80s prices. GAAP EPS before then is dominated by disposal gains, portfolio mark-to-market, and exploration expensing — i.e. noisy and not a reliable signal of business health. The bull case requires both the ramp to hit ~1.5M lbs and the ceilings to reset — a 2027+ story. (No Brier forecast logged — watchlist mode.)
Adversarial, institutional.
Bull case. enCore is one of a handful of operating US ISR uranium producers, in the best uranium tape in 18 years (spot ~$85, term ~$93 ), with a structural supply deficit (WNA: 438 reactors need ~178–180M lb/yr vs. constrained primary supply ) and an unprecedented US policy tailwind — FAST-41 fast-tracking of Dewey Burdock, DOE's $2.7B fuel-cycle program, the full Russian-uranium ban from Jan 2028, and the AI-data-center nuclear build-out (>10 GW of big-tech nuclear commitments; Palisades restart; TerraPower Natrium; SMRs). Extraction doubled YoY to 700k lbs and is heading toward Alta Mesa's 1.5M-lb capacity; extracted cash cost ($29–35/lb) is genuinely low. The stock has de-rated to ~$1.35 / ~$0.3B even as uranium hit multi-year highs — so a successful production ramp + ceiling reset + controls clean-up could drive a multi-bagger re-rate toward sell-side $5 targets. The Verdera spin hands shareholders a free option; the new founder-Chair + dealmaker-CEO could also make enCore an acquisition target for a larger producer wanting licensed US ISR capacity.
Bear case (risks that could permanently impair):
Pre-mortem (18 months out, thesis broke): Uranium spot drifts back to the $50s–60s as Sprott buying fades and secondary supply returns; Alta Mesa wellfields under-deliver vs the 1.5M-lb nameplate; enCore keeps buying spot at a loss to honour contracts; the class action survives a motion to dismiss and an accrual lands; a dilutive equity raise is needed; the founder-Chair/new-CEO disagree on strategy. EU re-rates to $0.80 and the "cheap producer" was cheap for cause.
Are multiples too high? On EV/Sales (~6–7x ) EU is cheap vs peers — the equity is not over-valued on the asset; the risk is value-trap, not bubble. The market is correctly pricing execution + governance risk, not mispricing the uranium.
Contrarian view (what the market refuses to see): Possibly that the de-rating has over-corrected — if Little remediates controls, the class action settles cheaply on D&O insurance, the ceilings reset in 2027, and Alta Mesa hits 1.2–1.5M lbs, enCore is a low-cost domestic producer trading at a fraction of asset value in a policy-protected market. The asymmetry could be attractive — but only after the controls + litigation overhang clears. Buying before that is buying the falling knife.
You are a skeptical short-seller dismantling the bull case.
A de-risked regulated-utility play on the data-center power buildout — the PSCW's April-2026 verbal approval of the VLC/Bespoke tariffs converts a $37.5B capex plan into a rate-base annuity, but at ~20x forward EPS the re-rating is mostly priced and the upside now lives in 2028 acceleration, not the multiple.
The purest non-utility way to own the AI-electricity buildout — a #2 infrastructure E&C contractor whose record $20.3B backlog and 34% Q1 growth are real, but the stock already prices ~40x forward EPS, so the bet is on the cycle's *duration*, not its existence.
A de-risked regulated growth utility hiding inside a decade-long value-trap reputation — the Loudoun County data-center boom is the largest demand tailwind in US utilities, but the equity only re-rates once CVOW finishes clean and the dividend finally grows; until then you are paid ~3.9% to wait on a BBB+ balance sheet stretched by a $65B capex plan.